RU2331646C2 - Новые соединения - Google Patents
Новые соединения Download PDFInfo
- Publication number
- RU2331646C2 RU2331646C2 RU2005121493/04A RU2005121493A RU2331646C2 RU 2331646 C2 RU2331646 C2 RU 2331646C2 RU 2005121493/04 A RU2005121493/04 A RU 2005121493/04A RU 2005121493 A RU2005121493 A RU 2005121493A RU 2331646 C2 RU2331646 C2 RU 2331646C2
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- pyridazin
- carbonyl
- isoxazolidinyl
- hydroxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 17
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 7
- 125000005842 heteroatom Chemical group 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 125000003118 aryl group Chemical group 0.000 claims abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000004122 cyclic group Chemical class 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- BAGAXAZIYONCTO-SANMLTNESA-N 2-[(3,5-dimethyl-1-pyridin-2-ylpyrazol-4-yl)methyl]-3-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-5-methyl-7-propan-2-ylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NN(C=2N=CC=CC=2)C(C)=C1CC=1SC=2C(C(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@](C)(O)CO1 BAGAXAZIYONCTO-SANMLTNESA-N 0.000 claims 1
- WBJKZNUEBLYOBR-HNNXBMFYSA-N 2-[(3,5-dimethyl-1-pyridin-2-ylpyrazol-4-yl)methyl]-7-ethyl-3-[(4s)-4-hydroxy-1,2-oxazolidine-2-carbonyl]-5-methylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NN(C=2N=CC=CC=2)C(C)=C1CC=1SC=2C(CC)=NN(C)C(=O)C=2C=1C(=O)N1C[C@H](O)CO1 WBJKZNUEBLYOBR-HNNXBMFYSA-N 0.000 claims 1
- OIWSCNLIZBUBKU-VWLOTQADSA-N 2-[(3,5-dimethyl-1-pyridin-2-ylpyrazol-4-yl)methyl]-7-ethyl-3-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-5-methylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NN(C=2N=CC=CC=2)C(C)=C1CC=1SC=2C(CC)=NN(C)C(=O)C=2C=1C(=O)N1C[C@](C)(O)CO1 OIWSCNLIZBUBKU-VWLOTQADSA-N 0.000 claims 1
- XXTOWQJOBJZSEY-VWLOTQADSA-N 2-[(3,5-dimethyl-1-pyrimidin-2-ylpyrazol-4-yl)methyl]-3-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-5-methyl-7-propan-2-ylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NN(C=2N=CC=CN=2)C(C)=C1CC=1SC=2C(C(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@](C)(O)CO1 XXTOWQJOBJZSEY-VWLOTQADSA-N 0.000 claims 1
- LIGIZFGWSFQIKC-ZDUSSCGKSA-N 2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-3-[(4s)-4-hydroxy-1,2-oxazolidine-2-carbonyl]-5-methyl-7-(2-methylpropyl)thieno[2,3-d]pyridazin-4-one Chemical compound CC1=NNC(C)=C1CC=1SC=2C(CC(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@H](O)CO1 LIGIZFGWSFQIKC-ZDUSSCGKSA-N 0.000 claims 1
- ZIHOSOLLBUYLKY-LBPRGKRZSA-N 2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-3-[(4s)-4-hydroxy-1,2-oxazolidine-2-carbonyl]-5-methyl-7-propan-2-ylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NNC(C)=C1CC=1SC=2C(C(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@H](O)CO1 ZIHOSOLLBUYLKY-LBPRGKRZSA-N 0.000 claims 1
- JDJZBFLLHALONW-QFIPXVFZSA-N 2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-3-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-5-methyl-7-(2-methylpropyl)thieno[2,3-d]pyridazin-4-one Chemical compound CC1=NNC(C)=C1CC=1SC=2C(CC(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@](C)(O)CO1 JDJZBFLLHALONW-QFIPXVFZSA-N 0.000 claims 1
- CKZFTDIKFACDMM-NSHDSACASA-N 2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-5-methyl-3-[(4s)-4-methyl-1,2-oxazolidine-2-carbonyl]-7-propan-2-ylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NNC(C)=C1CC=1SC=2C(C(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@H](C)CO1 CKZFTDIKFACDMM-NSHDSACASA-N 0.000 claims 1
- GQUIXLOQPRBJNH-NSHDSACASA-N 2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-7-ethyl-3-[(4s)-4-hydroxy-1,2-oxazolidine-2-carbonyl]-5-methylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NNC(C)=C1CC=1SC=2C(CC)=NN(C)C(=O)C=2C=1C(=O)N1C[C@H](O)CO1 GQUIXLOQPRBJNH-NSHDSACASA-N 0.000 claims 1
- HOIOIQPTCHIVDJ-FQEVSTJZSA-N 2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-7-ethyl-3-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-5-methylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NNC(C)=C1CC=1SC=2C(CC)=NN(C)C(=O)C=2C=1C(=O)N1C[C@](C)(O)CO1 HOIOIQPTCHIVDJ-FQEVSTJZSA-N 0.000 claims 1
- YPRAIPIHKGOOIK-DEOSSOPVSA-N 2-[[3,5-dimethyl-1-(1,3-thiazol-2-yl)pyrazol-4-yl]methyl]-3-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-5-methyl-7-propan-2-ylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NN(C=2SC=CN=2)C(C)=C1CC=1SC=2C(C(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@](C)(O)CO1 YPRAIPIHKGOOIK-DEOSSOPVSA-N 0.000 claims 1
- HVQDACFTLNKCPO-AWEZNQCLSA-N 3-[(4s)-4-hydroxy-1,2-oxazolidine-2-carbonyl]-5-methyl-7-(2-methylpropyl)-2-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyridazin-4-one Chemical compound C=1NC2=NC=CC=C2C=1CC=1SC=2C(CC(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@H](O)CO1 HVQDACFTLNKCPO-AWEZNQCLSA-N 0.000 claims 1
- ZSUQVIZBBAAIIH-AWEZNQCLSA-N 3-[(4s)-4-hydroxy-1,2-oxazolidine-2-carbonyl]-5-methyl-7-(2-methylpropyl)-2-[(1,3,5-trimethylpyrazol-4-yl)methyl]thieno[2,3-d]pyridazin-4-one Chemical compound CC1=NN(C)C(C)=C1CC=1SC=2C(CC(C)C)=NN(C)C(=O)C=2C=1C(=O)N1C[C@H](O)CO1 ZSUQVIZBBAAIIH-AWEZNQCLSA-N 0.000 claims 1
- JJFADIPQVDQFNB-LBPRGKRZSA-N 7-cyclopropyl-2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-3-[(4s)-4-hydroxy-1,2-oxazolidine-2-carbonyl]-5-methylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NNC(C)=C1CC1=C(C(=O)N2OC[C@@H](O)C2)C(C(=O)N(C)N=C2C3CC3)=C2S1 JJFADIPQVDQFNB-LBPRGKRZSA-N 0.000 claims 1
- FACVQJBQWNITOR-NRFANRHFSA-N 7-cyclopropyl-2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-3-[(4s)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-5-methylthieno[2,3-d]pyridazin-4-one Chemical compound CC1=NNC(C)=C1CC1=C(C(=O)N2OC[C@@](C)(O)C2)C(C(=O)N(C)N=C2C3CC3)=C2S1 FACVQJBQWNITOR-NRFANRHFSA-N 0.000 claims 1
- FLXIPFUVHRVGHE-ZDUSSCGKSA-N 7-cyclopropyl-2-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-5-ethyl-3-[(4s)-4-hydroxy-1,2-oxazolidine-2-carbonyl]thieno[2,3-d]pyridazin-4-one Chemical compound C1=2SC(CC3=C(NN=C3C)C)=C(C(=O)N3OC[C@@H](O)C3)C=2C(=O)N(CC)N=C1C1CC1 FLXIPFUVHRVGHE-ZDUSSCGKSA-N 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 0 **c1c(*)c(C(N(*)N=C2*)=O)c2[s]1 Chemical compound **c1c(*)c(C(N(*)N=C2*)=O)c2[s]1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300120A SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Novel compounds |
| SE0300120-3 | 2003-01-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005121493A RU2005121493A (ru) | 2006-02-20 |
| RU2331646C2 true RU2331646C2 (ru) | 2008-08-20 |
Family
ID=20290155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005121493/04A RU2331646C2 (ru) | 2003-01-17 | 2004-01-15 | Новые соединения |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7064126B2 (enExample) |
| EP (1) | EP1587809B1 (enExample) |
| JP (1) | JP4589298B2 (enExample) |
| KR (1) | KR20050092759A (enExample) |
| CN (1) | CN100358900C (enExample) |
| AT (1) | ATE375352T1 (enExample) |
| AU (1) | AU2004205617B2 (enExample) |
| BR (1) | BRPI0406780A (enExample) |
| CA (1) | CA2512736A1 (enExample) |
| DE (1) | DE602004009407T2 (enExample) |
| ES (1) | ES2293208T3 (enExample) |
| IL (1) | IL169363A (enExample) |
| IS (1) | IS2503B (enExample) |
| MX (1) | MXPA05007494A (enExample) |
| NO (1) | NO20053827L (enExample) |
| NZ (1) | NZ541216A (enExample) |
| PL (1) | PL378223A1 (enExample) |
| RU (1) | RU2331646C2 (enExample) |
| SE (1) | SE0300120D0 (enExample) |
| UA (1) | UA80175C2 (enExample) |
| WO (1) | WO2004065393A1 (enExample) |
| ZA (1) | ZA200505273B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117583D0 (en) * | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
| GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| JP2006515880A (ja) * | 2003-01-17 | 2006-06-08 | アストラゼネカ・アクチエボラーグ | 自己免疫疾患の調節におけるチエノピリダジノンとその使用 |
| SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| US7504509B2 (en) | 2003-12-19 | 2009-03-17 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| WO2007013896A2 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| TWI473808B (zh) | 2005-06-22 | 2015-02-21 | Plexxikon Inc | 用於激酶調節的化合物及方法及其適應症 |
| ES2559521T3 (es) * | 2006-10-16 | 2016-02-12 | Thesan Pharmaceuticals, Inc. | Pirazolil tienopiridinas terapéuticas |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| JP2010514695A (ja) | 2006-12-21 | 2010-05-06 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物および方法およびそのための適応症 |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| MX2012005284A (es) | 2009-11-06 | 2012-06-28 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello. |
| KR101911972B1 (ko) | 2011-02-07 | 2018-10-25 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| US9200005B2 (en) * | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| PT3060562T (pt) * | 2013-10-21 | 2021-09-02 | Genosco | Compostos de pirimidina substituídos e sua utilização como inibidores da syk |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999029695A1 (en) * | 1997-12-05 | 1999-06-17 | Astrazeneca Uk Limited | Novel compounds |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3620860A1 (de) * | 1986-06-21 | 1987-12-23 | Basf Ag | Substituierte acrylsaeureester und fungizide, die diese verbindungen enthalten |
| SE9702001D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| US6469014B1 (en) * | 1997-05-28 | 2002-10-22 | Astrazeneca Ab | Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy |
| ES2211161T3 (es) | 1998-08-28 | 2004-07-01 | Astrazeneca Ab | Tieno(2,3-d)pirimidindionas novedosas, procedimiento para su preparacion y uso de las mismas en terapia. |
| GB0117583D0 (en) * | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
| GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| JP2006515880A (ja) | 2003-01-17 | 2006-06-08 | アストラゼネカ・アクチエボラーグ | 自己免疫疾患の調節におけるチエノピリダジノンとその使用 |
-
2003
- 2003-01-17 SE SE0300120A patent/SE0300120D0/xx unknown
-
2004
- 2004-01-15 MX MXPA05007494A patent/MXPA05007494A/es active IP Right Grant
- 2004-01-15 AT AT04702471T patent/ATE375352T1/de not_active IP Right Cessation
- 2004-01-15 JP JP2006500749A patent/JP4589298B2/ja not_active Expired - Fee Related
- 2004-01-15 NZ NZ541216A patent/NZ541216A/en not_active IP Right Cessation
- 2004-01-15 BR BR0406780-0A patent/BRPI0406780A/pt not_active IP Right Cessation
- 2004-01-15 RU RU2005121493/04A patent/RU2331646C2/ru not_active IP Right Cessation
- 2004-01-15 AU AU2004205617A patent/AU2004205617B2/en not_active Ceased
- 2004-01-15 WO PCT/SE2004/000051 patent/WO2004065393A1/en not_active Ceased
- 2004-01-15 DE DE602004009407T patent/DE602004009407T2/de not_active Expired - Lifetime
- 2004-01-15 CA CA002512736A patent/CA2512736A1/en not_active Abandoned
- 2004-01-15 PL PL378223A patent/PL378223A1/pl unknown
- 2004-01-15 ES ES04702471T patent/ES2293208T3/es not_active Expired - Lifetime
- 2004-01-15 KR KR1020057013124A patent/KR20050092759A/ko not_active Abandoned
- 2004-01-15 US US10/542,194 patent/US7064126B2/en not_active Expired - Fee Related
- 2004-01-15 CN CNB2004800071016A patent/CN100358900C/zh not_active Expired - Fee Related
- 2004-01-15 UA UAA200506375A patent/UA80175C2/uk unknown
- 2004-01-15 EP EP04702471A patent/EP1587809B1/en not_active Expired - Lifetime
-
2005
- 2005-06-23 IL IL169363A patent/IL169363A/en not_active IP Right Cessation
- 2005-06-29 ZA ZA200505273A patent/ZA200505273B/xx unknown
- 2005-08-15 NO NO20053827A patent/NO20053827L/no not_active Application Discontinuation
- 2005-08-15 IS IS7982A patent/IS2503B/is unknown
-
2006
- 2006-06-06 US US11/447,343 patent/US20060223809A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999029695A1 (en) * | 1997-12-05 | 1999-06-17 | Astrazeneca Uk Limited | Novel compounds |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20053827L (no) | 2005-10-17 |
| JP4589298B2 (ja) | 2010-12-01 |
| IS7982A (is) | 2005-08-15 |
| ES2293208T3 (es) | 2008-03-16 |
| EP1587809A1 (en) | 2005-10-26 |
| ATE375352T1 (de) | 2007-10-15 |
| IS2503B (is) | 2009-04-15 |
| US20060223809A1 (en) | 2006-10-05 |
| CA2512736A1 (en) | 2004-08-05 |
| ZA200505273B (en) | 2006-04-26 |
| DE602004009407T2 (de) | 2008-07-24 |
| AU2004205617A1 (en) | 2004-08-05 |
| RU2005121493A (ru) | 2006-02-20 |
| PL378223A1 (pl) | 2006-03-20 |
| EP1587809B1 (en) | 2007-10-10 |
| CN1761670A (zh) | 2006-04-19 |
| JP2006515373A (ja) | 2006-05-25 |
| HK1081958A1 (en) | 2006-05-26 |
| DE602004009407D1 (de) | 2007-11-22 |
| CN100358900C (zh) | 2008-01-02 |
| IL169363A (en) | 2011-02-28 |
| NZ541216A (en) | 2008-05-30 |
| AU2004205617B2 (en) | 2007-03-08 |
| MXPA05007494A (es) | 2005-09-21 |
| NO20053827D0 (no) | 2005-08-15 |
| IL169363A0 (en) | 2007-07-04 |
| WO2004065393A1 (en) | 2004-08-05 |
| US7064126B2 (en) | 2006-06-20 |
| KR20050092759A (ko) | 2005-09-22 |
| SE0300120D0 (sv) | 2003-01-17 |
| US20060052380A1 (en) | 2006-03-09 |
| BRPI0406780A (pt) | 2006-01-17 |
| UA80175C2 (en) | 2007-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2331646C2 (ru) | Новые соединения | |
| KR101626996B1 (ko) | 벤조피란 및 벤족세핀 ｐｉ３ｋ 저해제 화합물 및 이의 사용 방법 | |
| ES2916449T3 (es) | Inhibidores de DCN1 de molécula pequeña covalentes y métodos terapéuticos de uso de los mismos | |
| RU2331647C2 (ru) | Тиенопиримидиндионы и их применение в модулировании аутоиммунного заболевания | |
| JP5546636B2 (ja) | ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法 | |
| KR102676822B1 (ko) | Atr 키나아제의 헤테로시클릭 저해제 | |
| KR101605063B1 (ko) | 소화관 운동이상이 관여하는 질환의 치료용 산 펌프 길항제 | |
| AU2019356011B2 (en) | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors | |
| WO2002032900A3 (en) | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | |
| RU2011116230A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| KR920019794A (ko) | 융합 헤테로시클릭 화합물, 그의 제조방법 및 용도 | |
| AU2014230812B2 (en) | Process for making benzoxazepin compounds | |
| KR970707131A (ko) | 티에노피리딘 또는 티에노피리미딘 유도체 및 그의 용도(thienopyridine or thienopyrimidine derivatives and their use) | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| RU2009120229A (ru) | Производные хинуклидинола в качестве антагонистов мускариновых рецепторов | |
| RU2013136778A (ru) | Ингибиторы гистондезацетилазы, композиции и способы их применения | |
| RU2341527C1 (ru) | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ | |
| AU2021300831B2 (en) | RIP1k inhibitors | |
| JP2003529593A5 (enExample) | ||
| ES2332137T3 (es) | Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso. | |
| BR112020009290A2 (pt) | derivados de pirimidina para a prevenção e tratamento de infecções bacterianas | |
| RU2006138606A (ru) | Ингибиторы киназы | |
| RU2007112675A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| RU2007126968A (ru) | Пиразологетероарильные соединения, применяемые для лечения болезней, опосредуемых tnf-a и il-1 | |
| ES2227139T3 (es) | Derivados de tienopiridina y su uso como agentes anti-inflamatorios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120116 |